In this article, Andrea Cusack, Chief Executive Officer, Elijah Nazarzadeh, PhD, Co-Founder and Chief Scientific Officer, and John Pritchard, PhD, Chairman, all at Nebu-Flow, share insights into Nebu~flow’s innovative nebuliser platform, designed to overcome the technical restrictions of current technologies that limit the delivery of advanced medicines to the lungs.

Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are major causes of death and disability worldwide, despite medical advancements.1 Researchers face two types of challenges. Firstly, there is a treatment gap for respiratory disorders, with most medicines focusing on symptom relief and preventing deterioration rather than providing an effective treatment.2,3 Secondly, selection of the delivery route and correct drug delivery device has proven to be a challenge in the treatment of respiratory disorders.

Although the best route of delivery for respiratory treatment is the direct delivery of drugs to the lungs through the inhalation route, the lack of a high-performing device, coupled with the low efficacy of drugs, usually results in selection of the parenteral route. This route usually requires a higher dose of medicine, which can result in higher exposure and toxicity.

To address these challenges, clinicians and researchers are seeking optimal drug formulations and delivery devices to target specific lung areas.

You can read the rest of this article on the On Drug Delivery website, found on the link below: